We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors. ×
Market Research Report

Global Coronavirus Treatment Market Outlook 2019-2035 : Market Size, Trends, Growth, Opportunities

Published Date :

2021-03-01

Report Pages :

285

Format :

PDF

Region Covered :

Global

Coronavirus Treatment Market Overview

Coronavirus is the type of virus that belongs to either of the two subfamilies basically called Coronavirinae and Torovirinae and they generally affects the respiratory track of mammals. They are non - segmented positive RNA viruses belonging to this family. Human Coronavirus were discovered in 1961 which affected the common cold. Most of the human coronavirus infections are mild, the epidemics of the two betacorona viruses, severe acute respiratory syndrome coronavirus and Middle East Respiratory Syndrome cornovirus which have caused more than 10,000 cumulative cases in the last decade. These viruses cause a range of serious infections in humans from common cold to severe respiratory problems. Coronavirus spreads through droplets i.e . by coughing , sneezing and there is limited possibility that this virus could spread by close contacts with the ability to pass from person to person. Sore throat, coughing, fever, respiratory infection and difficulty in breathing are some of the most common symptoms of coronavirus infection.The clinical signs and symptoms reported are mainly fever, with a few cases having difficulty in breathing, and chest radiographs showing invasive pneumonic infiltrates in both lungs.

In 2002 Sars spread virtually unchecked to 37 countries, causing global panic, infecting more than 8,000 people and killing more than 750. Mers appears to be less easily passed from human to human, but has greater lethality, killing 35% of about 2,500 people who have been infected.An international outbreak of respiratory illness caused by a novel coronavirus has killed at least 56 people and sickened at least 2,000, according to the Chinese health authorities.The outbreak began in Wuhan, China at a market selling live poultry, seafood and wild animals. Virus from open selling had turned to about 11 countries including Japan, South Korea, France , Australia and the United States.The total economy is of USD$ 40 billion.

Coronavirus Treatment Market Segmentation

Based on the infections caused by coronavirus infection, the market can be segmented as follows:

  • HCoV-229E: causes common cold, pneumonia, and bronchiolitis
  • HCoV-OC43: causes respiratory tract infection and pneumonia in infants
  • SARS-CoV: causes severe acute respiratory syndrome (SARS)
  • New Haven CoV: causes Kawasaki disease, aneurysms of the coronary arteries
  • HKU1-CoV: causes acute respiratory distress and bilateral pneumonia
  • MERS-CoV (Middle East respiratory syndrome coronavirus): causes bronchial infections
  • Standard precaution:

Hand hygiene,

Eye protection,

Mouth Protection,

Disinfection of equipment’s etc.

  • Droplet precaution:

Use of medical/ordinary mask

Restricted patient movement

  • Airborne precaution:

Use of PPE (personal protective equipment), hand gloves etc.

Research and Development activities

1. Biocryst Pharmaceuticals

Biocryst Pharmaceuticals surged briefly last week with fears rising about the coronavirus outbreak. The company's development focuses on antiviral drugs.The company's only commercial product, Rapivab, was approved by the U.S. Food and Drug Administration in 2014 to treat influenza infection. However, the influenza virus, commonly known as the flu virus, doesn't belong to the family of coronaviruses. Biocryst is, though, evaluating a drug, galidesivir, that could potentially target the coronavirus that's infected hundreds of people. Galidesivir is currently in a phase 1 clinical study.

2. Gilead Sciences

One of the biggest biotechs in the world, Gilead Sciences , is well-known for its drugs that treat the hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Gilead continues to make billions of dollars each year from its HCV and HIV franchises.The big biotech is now thinking about evaluating its antiviral drug remdesivir, which targets Ebola virus and Marburg virus, as a potential coronavirus treatment. Reuters reported last week that Gilead is in discussions with researchers in China and the U.S. about the potential for remdesivir to be used in treating the coronavirus.

3. Inovio

Inovio has focused on infectious diseases for years but doesn't have an approved drug on the market yet. The company's most advanced program is VGX-3100, a DNA vaccine that targets cervical dysplasia caused by human papillomavirus. Inovio expects to report results from a late-stage study of VGX-3100 in late 2020.The coronavirus threat has bolstered interest in Inovio's antiviral programs. Inovio's share price jumped last week after the Coalition for Epidemic Preparedness Innovations gave the biotech a grant of up to $9 million to develop a vaccine for the coronavirus strain that's causing concerns.

4. Moderna

Another biotech stock that has gained a lot of attention as worries escalated about the coronavirus is Moderna Like Inovio, Moderna recently received a grant from CEPI to develop a coronavirus vaccine.Moderna already has five experimental vaccines in testing that use messenger RNA (mRNA) to prevent or control viral infections, including mRNA vaccines targeting respiratory syncytial virus and Zika virus. The biotech thinks that its mRNA approach could "stimulate a more potent immune response" and potentially set the stage for "rapid discovery to respond to emerging pandemic threats.

5. Novavax

Novavax emerged as one of the biggest movers among biotech stocks in the wake of the coronavirus scare. The biotech's shares soared over 30% last week with Novavax announcing that it's working on a coronavirus vaccine.While Novavax shifts some resources to focus on the coronavirus, the biotech's lead candidate is its nanoparticle-based flu vaccine NanoFlu. Novavax expects to report results from a late-stage clinical study of the vaccine later in the first quarter of 2020.

Number of cases around the world-

As of Sunday, case numbers had reached over 2,000 in China and abroad. Chinese authorities also confirmed that health workers have been infected with the virus, suggesting that human-to-human transmission is possible. The bulk are in China, with a total of 17 cases reported in Taiwan, Hong Kong and Macau. Internationally, a handful of cases have been confirmed in Thailand, Japan, South Korea, Malaysia and Vietnam. In the US, five cases have been confirmed: Two in California and one each in Washington, Illinois and Arizona. Australia has seen five cases, France three. Canadian authorities announced its first "presumptive" case on Saturday, a male in his 50s who had traveled through Wuhan.

Here's the breakdown as it stands:

  • China: 2,079 confirmed cases
  • Thailand: 8 confirmed cases
  • US: 5 confirmed cases
  • Australia: 5 confirmed cases
  • Japan: 4 confirmed cases
  • Malaysia: 4 confirmed cases
  • Singapore: 4 confirmed cases
  • France: 3 confirmed cases
  • South Korea: 3 confirmed cases
  • Vietnam: 2 confirmed cases
  • Canada: 1 presumptive case
  • Nepal: 1 confirmed case

National authorities in China continue to monitor more than 1,300 residents who visited the Wuhan market or have had prolonged contact with those presenting symptoms of the disease. The death toll stands at 80. The first reported death in Hubei province was a 61-year-old man who'd frequented the Wuhan market and had chronic liver disease and abdominal tumors. The second was a 69-year-old man who went to a hospital with severe damage to multiple organs. The virus has taken two lives outside the Hubei epicenter -- one person in Hebei province, more than 600 miles north of Wuhan, and another in Heilongjiang province, which is more than 1,500 miles from Wuhan and near the Russian border.

Types of treatment available

Coronaviruses are hardy organisms. They're effective at hiding from the human immune system, and there has not been any development for any reliable treatments or vaccines that can eradicate them. In most cases, health officials attempt to deal with the symptoms."There is no recognized therapeutic against coronaviruses.The primary objective in an outbreak related to a coronavirus is to give adequate support of care to patients, particularly in terms of respiratory support and multi-organ support. That doesn't mean vaccines are an impossibility, however. Chinese scientists were able to sequence the virus' genetic code incredibly quickly, giving scientists a chance to study it and look for ways to combat the disease. According to research, researchers at the US National Institutes of Health are already working on a vaccine, though it could be a year or more away from release.

Notably, SARS, which infected around 8,000 people and killed around 800, seemed to run its course and then mostly disappear. It wasn't a vaccine that turned the tide on the disease but rather effective communication between nations and a range of tools that helped track the disease and its spread. The main treatment is supportive care, including making sure the patient is getting enough oxygen, and using a ventilator to push air into the lungs if necessary. Patients should rest and drink plenty of fluids “while the immune system does its jobs and heals itself”. No drugs have been approved for any coronavirus diseases, including the Wuhan coronavirus, though an antiviral medication called remdesivir appears to be effective in animals.

Scientists were very quick to identify the virus, and officials with the National Institutes of Health said that advances in technology may make it possible to test a vaccine against the Wuhan coronavirus within three months. There is no vaccine for the new coronavirus but researchers at the U.S. National Institutes of Health confirmed they were in preliminary stages of developing one. In addition, the drug company Regeneron announced that it is in the early stages of developing a treatment for this virus.

Coronavirus Treatment Market Dynamics

Growth Driver and Challenges

Major driving factors for the growth of coronary infection market are increase in the rate of communicable diseases, increasing disposable income in emerging and developing countries, increasing number of hospitals, and rising health hygiene of individuals across geographies. Technological advancement and innovation about respiratory infection treatment has also triggered the growth of the coronary infection market. On the other hand, huge amount of capital involved in the market would most likely impede the growth of this market.

Geographical Markets (Dominate Market/Target Opportunities)

Wuhan city is a major domestic and international transport hub.While most people affected are in China, cases in this fast-moving outbreak have now been found in the United States, France, Australia, Hong Kong, Thailand, Malaysia, South Korea, Taiwan, Macau, Japan and the Philippines. Fourteen people are being tested in the United Kingdom.The city of Macau, a gambling hub hugely popular with mainland tourists, has confirmed five cases as of Sunday. In Hong Kong, six people are known to have the disease.As of January 26, the virus has continued to spread internationally, with the United States recording five confirmed cases. France has confirmed three cases, Singapore has four while Nepal has identified its first and Thailand its eighth.Elsewhere in Asia, Taiwan has uncovered four cases so far, South Korean reported the country's third case, and Vietnam confirmed two cases. Malaysia and Japan have both confirmed four cases. Australia has confirmed it has five confirmed cases of the virus.The disease has spread to major cities like Beijing, Shanghai, and Shenzhen—as well as to neighboring Taiwan, Thailand, Japan, and South Korea—in just three weeks. It has been found in cities all over China, and travelers have since spread the virus to several countries, including Singapore, Japan, Vietnam, Taiwan and South Korea as well as Hong Kong and Macau.

Geographically, North America holds a leading position in the coronary infection market followed by Europe. The prime driving factors for the growth of this market in these regions are increasing awareness among people regarding infectious viruses such as SARS-CoV, shift to sophisticated technological treatment tools, and constantly increasing segment of the population who acquire coronavirus infection. According to the World Health Organization (WHO), around 1.1 million people in the United States were hospitalized with pneumonia and 50,000 people died from this disease. Asia-Pacific is one of the fastest growing regions and is the most lucrative market as this region is expected to show a rapid growth in the near future. Major factors that will boost the growth of the coronavirus infection market in Asia-Pacific are high population density in countries like China and India where there is high prevalence of contagious diseases, improved healthcare infrastructure, and demand for novel drug therapeutics related to coronavirus infected diseases.

Mergers and Acquisitions

The investigational DNA immunotherapy, INO-4700 (GLS-5300) is being developed by Inovio in partnership with GeneOne Life Science. It is delivered as vaccine intramuscularly, using the Cellectra® delivery device.The vaccine was well-tolerated and demonstrated high immune responses against the MERS-CoV in 94% of patients in the early-stage clinical trial in July 2019.It also generated broad-based T cell responses in 88% of the subjects.

Biocryst Pharma’s Galidesivir, a potential antiviral for coronavirus treatment

The antiviral drug Galidesivir (BCX4430) has shown broad-spectrum activity against a wide range of pathogens including coronavirus. It is a nucleoside RNA polymerase inhibitor that disrupts the process of viral replication.The drug has already shown survival benefits in patients against deadly viruses such as Ebola, Zika, Marburg, and Yellow fever.Galidesivir is currently in advanced development stage under the Animal Rule to combat multiple potential viral threats including coronaviruses, flaviviruses filoviruses, paramyxoviruses, togaviruses, bunyaviruses, and arenaviruses.

Competitive Landscape

Some of the top major players operating in the coronavirus market are :-

  • Inovio Pharmaceuticals Inc.
  • Novavax Inc.
  • Protein Potential
  • LLC
  • AlphaVax Inc.
  • Synairgen plc
  • NanoViricides Inc.
  • GGeneCure
  • LLC and many others.

For a full detailed overview, send here request for market report sample. 




{ }

Global Coronavirus Treatment Market Outlook 2019-2035 : Market Size, Trends, Growth, Opportunities

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR Call Us:+1-646-568-7747

Table of Contents

Please Select Linenece Type